Apligraf

Apligraf. It is a bilayer living cell-based skin substitute designed to mimic the structure and function of natural human skin. Comprising both an epidermis and a dermis, it is used as a biological dressing to promote wound healing in specific chronic conditions. Its development marked a significant advancement in the field of tissue engineering and regenerative medicine.

Description and Composition

Apligraf is a sophisticated biomaterial constructed from two primary layers. The dermal layer is composed of type I bovine collagen populated with living human dermal fibroblasts derived from neonatal foreskin. The epidermal layer is formed by cultivating human keratinocytes on the surface of this dermal matrix, which then stratify to create a cornified outer layer. This structure is metabolically active, secreting essential growth factors and extracellular matrix proteins, but it lacks other cell types such as melanocytes, Langerhans cells, and blood vessels.

Medical Uses and Indications

This product is specifically indicated for the treatment of two challenging chronic wounds. Its primary use is for venous leg ulcers that are refractory to conventional therapy, including adequate compression therapy. It is also approved for use in full-thickness neuropathic diabetic foot ulcers of greater than three weeks duration, which have not adequately responded to standard wound care protocols. It is not indicated for burns or other acute wounds.

Mechanism of Action

The mechanism by which Apligraf facilitates healing involves both physical and biological actions. Upon application, it provides immediate wound coverage, acting as a protective barrier against infection and desiccation. The living cells within the graft secrete a milieu of cytokines and matrix proteins, such as vascular endothelial growth factor and collagen, which are critical for cellular recruitment and tissue regeneration. This activity helps to modulate the local wound microenvironment, shifting it from a state of chronic inflammation towards a proliferative healing phase.

Clinical Efficacy and Studies

The approval and adoption of Apligraf were supported by pivotal randomized controlled trials published in journals like the Journal of the American Medical Association and Wound Repair and Regeneration. In studies for venous ulcers, treatment with Apligraf combined with compression demonstrated significantly higher complete wound closure rates compared to compression therapy alone. Similarly, for diabetic foot ulcers, trials showed improved healing rates versus standard care, which typically involves saline-moistened gauze and off-loading devices like total contact casts.

Manufacturing and Regulatory Status

Apligraf is manufactured by Organogenesis Inc. through a proprietary process involving aseptic technique and cell culture. As a biologic product containing living human cells, it is regulated as a medical device under section 361 of the Public Health Service Act and relevant regulations from the Food and Drug Administration. It has a limited shelf-life and requires specific storage conditions. It received FDA approval for venous leg ulcers in 1998 and for diabetic foot ulcers in 2000, making it one of the first such products to reach the market.

History and Development

The development of Apligraf originated from pioneering research in cell biology and tissue engineering conducted at institutions like Massachusetts Institute of Technology and Harvard Medical School. Key scientific work involved creating three-dimensional skin models for toxicology testing. The technology was subsequently commercialized, with critical clinical trials conducted at major wound care centers such as the University of Miami Hospital and the Cleveland Clinic. Its introduction represented a landmark in applying principles of regenerative medicine to clinical practice. Category:Medical treatments Category:Tissue engineering